The European Journal of Health Economics

, Volume 11, Issue 1, pp 67–76

Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis

Original Paper



Infliximab has been shown to be efficacious in acute exacerbations of ulcerative colitis (UC).


To evaluate the cost-effectiveness of infliximab treatment in patients hospitalised with acute exacerbations of UC.


A decision analysis model was constructed to simulate the progression of acute UC patients treated with infliximab induction regimen over 1 year. Infliximab treatment was compared with standard care, ciclosporin and surgery using transitions derived from infliximab and ciclosporin randomised trials. Costs and outcomes were discounted at 3.5%. Intermediate outcomes of colectomy and post-surgery complications were translated into the primary effectiveness measurement, which was quality-adjusted life years (QALYs) estimated using EQ-5D. One-way and probabilistic sensitivity analyses were performed to estimate the uncertainty around the results.


The incremental cost effectiveness ratio (ICER) for infliximab was £19,545 per QALY compared to ciclosporin, which in turn dominated standard care. Sensitivity analysis indicated patient body weight, utility estimates and treatment effect of alternative treatment strategies to be the most important factors affecting cost-effectiveness.


Infliximab induction regimen appears to be a cost-effective treatment option for UC patients hospitalised with an acute exacerbation.


Cost effectiveness Acute Ulcerative colitis Infliximab 

JEL Classification



  1. 1.
    Carter, M.J., Lobo, A.J., Travis, S.P.: Guidelines for the management of inflammatory bowel disease in adults. Gut 53(5), V1–V16 (2004)CrossRefGoogle Scholar
  2. 2.
    Jarnerot, G., Rolny, P., Sandberg-Gertzen, H.: Intensive intravenous treatment of ulcerative colitis. Gastroenterology 89(5), 1005–1013 (1985)Google Scholar
  3. 3.
    Truelove, S.C., Jewell, D.P.: Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1(7866), 1067–1070 (1974)CrossRefGoogle Scholar
  4. 4.
    Leiper, K., Lowe, D., Driscoll, R., et al.: UK IBD audit 2006: National results for the organisation and process of IBD care in the UK. Published 2007; available at
  5. 5.
    Travis, S., Trange, E., Lemann, A., et al.: European evidence based consensus on the diagnosis and management of ulcerative colitis: current management. J. Crohn’s Colitis 2, 24–62 (2008)CrossRefGoogle Scholar
  6. 6.
    Arts, J., D’Haens, G., Zeegers, M., et al.: Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflam. Bowel Dis. 10, 73–78 (2004)CrossRefGoogle Scholar
  7. 7.
    Sandborn, W.J.: A critical review of cyclosporine therapy in inflammatory bowel disease. Inflam. Bowel Dis. 1, 48–63 (1995)CrossRefGoogle Scholar
  8. 8.
    Jarnerot, G., Hertervig, E., Friis-liby, I., et al.: Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized placebo controlled study. Gastroenterology 128, 1805–1811 (2005)CrossRefGoogle Scholar
  9. 9.
    Sands, B.E., Tremaine, W.J., Sandborn, W.J., Rutgeerts, P.J., Hanauer, S.B., Mayer, L., Targan, S.R., Podolsky, D.K.: Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflam. Bowel Dis. 7(2), 83–88 (2001)CrossRefGoogle Scholar
  10. 10.
    Tsai, H.H., Punekar, Y.S., Morris, J., et al.: A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis. Aliment. Pharmacol. Ther. 15;28(10), 1230–1239 (2008)CrossRefGoogle Scholar
  11. 11.
    D’Haens, G., Lemmens, L., Geboes, K., et al.: Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 120(6), 1323–1329 (2001)CrossRefGoogle Scholar
  12. 12.
    Lichtiger, S., Present, D.H., Kornbluth, A., et al.: Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N. Engl. J. Med. 330(26), 1841–1845 (1994)CrossRefGoogle Scholar
  13. 13.
    Ades, A., Welton, N., Caldwell, D., et al.: Multiparameter evidence synthesis in epidemiology and medical decision-making. J. Health Serv. Res. Policy 13(Suppl 3), 12–22 (2008)CrossRefGoogle Scholar
  14. 14.
    Lunn, D.J., Thomas, A., Best, N., Spiegelhalter, D.: WinBUGS–a Bayesian modelling framework: concepts, structure, and extensibility. Stat. Comput. 10, 325–337 (2000)CrossRefGoogle Scholar
  15. 15.
    Reference costs 2006/07: National schedule of reference costs. Department of Health. January 2008Google Scholar
  16. 16.
    Woehl, A., Hawthorne, B., Morgan, C., Punekar, Y., McEwan, P.: The epidemiology and healthcare resource use in patients with Crohn’s disease: a population based UK study. Value Health 10(6), A355 (2007)Google Scholar
  17. 17.
    Dolan, P.: Modeling valuations for EuroQol health states. Med. Care 35(11), 1095–1108 (1997)CrossRefGoogle Scholar
  18. 18.
    Walmsley, R.S., Ayres, R.C.S., Pounder, R.E., Allan, R.N.: A simple clinical colitis activity index. Gut 43(10), 29–32 (1998)CrossRefGoogle Scholar
  19. 19.
    Arseneau, K., Sultan, S., Provenzale, D., et al.: Do patient preferences influence decisions on treatment for patients with steroid refractory ulcerative colitis? Clin. Gastroenterol. Hepatol. 4(9), 1135–1142 (2006)CrossRefGoogle Scholar
  20. 20.
    National Institute of Health and Clinical Excellence (NICE): Guide to the Methods of Technology Appraisal (reference NO515). NICE, London, (2004),
  21. 21.
    Kohn, A., Daperno, M., Armuzzi, A., et al.: Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. Aliment. Pharmacol. Ther. 26(5), 747–756 (2007)CrossRefGoogle Scholar
  22. 22.
    National Institute of Health and Clinical Excellence (NICE). Guidance on the Use of Infliximab for Psoriasis. London: Technology Appraisal Guidance 134, January (2008),
  23. 23.
    Laharie, D.: A randomized, multicenter open label study comparing cyclosporine with infliximab in steroid-refractory severe attacks of ulcerative colitis (CYSIF). identifier–NCT00542152,

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  1. 1.Schering-Plough LtdWelwyn Garden CityUK
  2. 2.Oxford OutcomesOxfordUK

Personalised recommendations